Data are non-existent regarding coincidental alterations in the expression of p53 and its downstream target genes MDM2 and p21 Waf1/Cip1 in gastric carcinogenesis. An immunohistochemical study was therefore performed to examine the interrelationships of p53, MDM2, and p21 Waf1/Cip1 expression in a s
The clinical significance of p21WAF1/CIP-1 and p53 expression in pancreatic adenocarcinoma
โ Scribed by Sanaa T. Dergham; Michael C. Dugan; Urwashi S. Joshi; Yong C. Chen; Wei Du; Daryn W. Smith; Patricia Arlauskas; John D. Crissman; Vainutis K. Vaitkevicius; Fazlul H. Sarkar
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 300 KB
- Volume
- 80
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
โฆ Synopsis
the pancreas were immunostained for p53 and p21. Nuclear expression was scored as absent, focal (รต10%), moderate (10 -50%), or strong or diffuse
๐ SIMILAR VOLUMES
Defects in the mechanisms controlling the cell cycle are crucial in cell transformation and/or tumour progression. p21 WAF1/CIP1 is an inhibitor of cyclin-dependent kinases, induced by p53-dependent and p53-independent pathways, which can block progression through the cell cycle. p21 WAF1/CIP1 expre
BACKGROUND. The clinical course of laryngeal squamous cell carcinoma (LSCC) varies considerably among patients. New biologic markers are needed to facilitate the stratification of individual patients within the conventional clinicopathologic stages of LSCC. METHODS. Eighty-three LSCCs from an equal
The cyclin-dependent kinase inhibitor p21/WAF1 is regulated by p53-dependent and p53-independent pathways. In addition, p21/WAF1 binds with proliferating cell nuclear antigen (PCNA) and inhibits the action of PCNA. To investigate the possible role of p21/WAF1 in human hepatocellular carcinomas (HCCs
BACKGROUND. p21(waf1/cip1) protein is a cyclin-dependent kinase inhibitor able to arrest the cell cycle at the G1 phase by inhibiting DNA replication. The expression of p21(waf1/cip1) and its prognostic value in prostate cancer are largely unexplored. METHODS. We used immunohistochemistry to analyze